The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer.
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rui Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Abraham Anderson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yun Lan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Timothy Iveson
Research Funding - Amgen
Other Remuneration - Amgen
Ross C. Donehower
Research Funding - Amgen
Yizhou Jiang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sarita Dubey
Employment or Leadership Position - Amgen
Elwyn Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen